A high-tech device that can monitor medication use and compliance has been cleared by the FDA for use with AstraZeneca’s Airsupra and Breztri inhalers.
AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
Enforcement Report - Week of July 19, 2023
Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) Due to Container Defect
AstraZeneca’s asthma marketing team is pushing the importance of inflammation in asthma. Across two unbranded campaigns targeting patients and healthcare professionals, the drugmaker is communicating a message that is aligned with the effects of its recently approved rescue inhaler Airsupra.
Cipla Issues Voluntary Nationwide Recall of Six Batches of Albuterol Sulfate Inhalation Aerosol Due to Container Defect
Enforcement Report - Week of June 7, 2023
FDA Confirms Paragraph IV Patent Litigation for Albuterol Sulfate and Ipratropium Bromide
The beginning of March saw manufacturer Akorn Pharmaceuticals file for Chapter 7 bankruptcy protection, which led to the closure of all its US manufacturing plants and hundreds of layoffs. But this also had a cascading effect leading to a shortage of albuterol, specifically the 0.5% version, which is used to treat breathing issues.